导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.13% | 3896/4773 |
| 近一周 | -1.48% | 469/5462 |
| 近一月 | -7.72% | 3946/5421 |
| 近一季 | -15.89% | 4353/5209 |
| 近半年 | -21.61% | 4465/4920 |
| 近一年 | -6.72% | 3194/4366 |
| 近两年 | 33.49% | 2144/2954 |
| 近三年 | 5.58% | 1829/2253 |
| 成立以来 | 4.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.99% 617/4961 |
0.81% 3122/5312 |
- - |
- - |
| 2025 | 27.63% 1546/4813 |
-4.29% 3154/3635 |
0.10% 2762/4076 |
35.43% 990/4524 |
-1.63% 2984/4813 |
| 2024 | 2.75% 1958/3463 |
-2.02% 1308/2808 |
-7.26% 2064/3014 |
18.46% 1002/3129 |
-4.54% 2476/3463 |
| 2023 | -27.96% 2029/2656 |
-2.89% 2055/2280 |
-5.47% 1467/2385 |
-14.28% 2177/2515 |
-8.46% 2291/2655 |
| 2022 | -23.49% 1138/2207 |
-14.87% 1008/1919 |
14.19% 206/2016 |
-15.98% 1382/2113 |
-6.32% 1988/2208 |
| 2021 | 42.42% 23/1822 |
-4.93% 897/1255 |
28.01% 55/1330 |
17.07% 67/1466 |
-0.04% 1188/1822 |
| 2020 | 54.01% 145/1250 |
-5.86% 440/1028 |
14.64% 540/1067 |
15.21% 229/1164 |
23.86% 38/1184 |
| 2019 | 20.05% 672/1092 |
24.53% 507/739 |
-9.46% 657/788 |
-1.10% 633/850 |
7.66% 413/918 |
| 2018 | -35.91% 582/834 |
- - |
-16.99% 570/631 |
-10.16% 535/660 |
-9.18% 134/682 |
| 2017 | 0.79% 468/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.88% 344/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发中证环保ETF联接A VS. 长安沪深300非周期A(740101) |